Ankle

Nonprofit Supporting Retired Military Working Dogs Celebrates Milestone

Retrieved on: 
Thursday, April 4, 2024
Ankle, Dog, United States Army, Emergency, Pain, Nox, Pharmaceutical industry

BALTIMORE, April 04, 2024 (GLOBE NEWSWIRE) -- A non-profit with over 23 years’ service, supporting the military K-9 community, is celebrating the successful rollout of a new program which covers the cost of emergency treatments for retired military working dogs.

Key Points: 
  • BALTIMORE, April 04, 2024 (GLOBE NEWSWIRE) -- A non-profit with over 23 years’ service, supporting the military K-9 community, is celebrating the successful rollout of a new program which covers the cost of emergency treatments for retired military working dogs.
  • US War Dogs Association has already provided $50,000 of treatments to retired MWDs through its Emergency Care program, alleviating the financial burden from their handlers and families.
  • Retired US Army patrol and explosive detection dog (PEDD), Nox, is a recent beneficiary of US War Dogs’ Emergency Care program.
  • “We are only able to continue our vital work of supporting the military K-9 community, thanks to the generosity of our donors.

Appointment of Stephen M. Deitsch as new Chief Financial Officer

Retrieved on: 
Thursday, April 4, 2024
Growth, CFO, Patient, Foot, Liver transplantation, IPO, Ankle, FNA, Management

OXFORD, United Kingdom, April 04, 2024 (GLOBE NEWSWIRE) -- OrganOx , a medical device company which is changing the paradigm in liver transplantation in the US and Europe with its groundbreaking normothermic machine perfusion technology, today announces that Stephen (Steve) M. Deitsch will be joining OrganOx as Chief Financial Officer (“CFO”) on April 8, 2024.

Key Points: 
  • OXFORD, United Kingdom, April 04, 2024 (GLOBE NEWSWIRE) -- OrganOx , a medical device company which is changing the paradigm in liver transplantation in the US and Europe with its groundbreaking normothermic machine perfusion technology, today announces that Stephen (Steve) M. Deitsch will be joining OrganOx as Chief Financial Officer (“CFO”) on April 8, 2024.
  • Steve’s leadership was instrumental in Paragon 28’s successful IPO on the NYSE in the fall of 2021.
  • Prior to Paragon 28, Steve held CFO roles in a range of public and privately held companies in both the US and Europe.
  • Craig Marshall, OrganOx Chief Executive Officer, said, “I am hugely looking forward to working with Steve as our new CFO.

Alira Health Joins Forces with APMA to Advance Podiatric Registry

Retrieved on: 
Wednesday, March 27, 2024
Real-World Evidence, Partnership, RWE, Health, Patient, Research, Foot, Ankle, American Podiatric Medical Association, Surgeon, CAE, MPH, APMA, DPM, Physician, Pharmaceutical industry

Framingham, Mass., March 27, 2024 (GLOBE NEWSWIRE) -- Alira Health , a global advisory and clinical research firm, joined the American Podiatric Medical Association (APMA), the largest professional association representing podiatrists, physicians and surgeons who treat the foot and ankle, as a corporate member to help advance APMA’s Podiatric Registry.

Key Points: 
  • Framingham, Mass., March 27, 2024 (GLOBE NEWSWIRE) -- Alira Health , a global advisory and clinical research firm, joined the American Podiatric Medical Association (APMA), the largest professional association representing podiatrists, physicians and surgeons who treat the foot and ankle, as a corporate member to help advance APMA’s Podiatric Registry.
  • The APMA registry supports researchers’ understanding of diseases and ways to treat them.
  • "APMA is excited by the opportunity to drive powerful research to improve patient care in conjunction with Alira Health," said APMA Senior Medical Director Dyane E. Tower, DPM, MPH, MS, CAE.
  • “Our partnership with APMA marks an advancement in accelerating innovation and new solutions for patients,” said Gabriele Brambilla, CEO of Alira Health.

AOFAS Awards More Than $250,000 in Grants to Fund Foot and Ankle Orthopaedic Research

Retrieved on: 
Tuesday, March 26, 2024
Emory University, Diagnosis, Success, Red carpet, Early Career Award, Resident, Safety, Knowledge, Research, Effect, Foot, Ankle, Key, Gait analysis, Health, Pharmaceutical industry

Rosemont Ill., March 26, 2024 (GLOBE NEWSWIRE) -- The American Orthopaedic Foot & Ankle Society (AOFAS) awarded its annual research grants to 9 promising foot and ankle research projects.

Key Points: 
  • Rosemont Ill., March 26, 2024 (GLOBE NEWSWIRE) -- The American Orthopaedic Foot & Ankle Society (AOFAS) awarded its annual research grants to 9 promising foot and ankle research projects.
  • With funding from the Orthopaedic Foot & Ankle Foundation , the AOFAS Research Grants Program provides AOFAS members and their research teams with the resources to discover new foot and ankle treatments and advance patient care.
  • “The AOFAS Research Grants Program supports foot and ankle orthopaedic surgeons’ important work with basic, translational, and clinical science,” said AOFAS Research Committee Chair Jason T. Bariteau, MD, from Emory University in Atlanta.
  • The AOFAS Research Grants Program is funded by the Orthopaedic Foot & Ankle Foundation, supported in part by a grant from Arthrex, Inc.

BlueWind Medical Revi™ Patient-Centric Solution for Urge Urinary Incontinence Now Available at Mount Carmel Health in Ohio

Retrieved on: 
Tuesday, April 9, 2024
Physician, Patient, Tibial, OASIS, Ankle, Quality of life, Pharmacotherapy, Urinary incontinence, Safety, Commercial software, Neuromodulation, FDA, Medical device

PARK CITY, Utah, April 9, 2024 /PRNewswire/ -- BlueWind Medical, Ltd., a trailblazer in patient-centric healthcare innovations, announced that distinguished urologist Dr. Jeffrey Carey of the Central Ohio Urology Group is now offering Revi implantable Tibial NeuroModulation (iTNM) solution for urge urinary incontinence (UUI).

Key Points: 
  • PARK CITY, Utah, April 9, 2024 /PRNewswire/ -- BlueWind Medical, Ltd., a trailblazer in patient-centric healthcare innovations, announced that distinguished urologist Dr. Jeffrey Carey of the Central Ohio Urology Group is now offering Revi implantable Tibial NeuroModulation (iTNM) solution for urge urinary incontinence (UUI).
  • "Many of my patients are looking for an alternative to ongoing drug therapy" shared Dr. Jeffrey Carey.
  • "Revi provides individually tailored therapy that patients deliver themselves, on their schedule, and at their convenience.
  • Coupled with the excellent safety and efficacy of Revi, it's a welcome choice for urge incontinence patients."

Paragon 28 Announces CFO Transition, Provides Preliminary Unaudited Net Revenue for First Quarter 2024, and Reaffirms Net Revenue Guidance for Fiscal Year 2024

Retrieved on: 
Thursday, April 4, 2024
Surgery, Health, Medical Devices, Paragon, Growth, CFO, Webcast, Knowledge, Foot, Ankle, FNA, Interim management, Interim, Audit committee

The Company concurrently announced the appointment of Kristina Wright as Interim CFO, effective April 3, 2024.

Key Points: 
  • The Company concurrently announced the appointment of Kristina Wright as Interim CFO, effective April 3, 2024.
  • Thomas Schnettler, lead independent director for Paragon 28, will assume the role of interim Chair of the Audit Committee.
  • The Company reaffirms its prior 2024 net revenue guidance and continues to expect 2024 net revenue to be $249 million to $259 million, representing 15.1% and 19.7% reported growth compared to 2023.
  • Paragon 28 will report first quarter 2024 financial results after market close on Wednesday, May 8, 2024.

Henry Schein Completes Acquisition of Majority Interest of TriMed, Inc.

Retrieved on: 
Thursday, April 4, 2024
Medical Devices, Health, Dental, Physical Therapy, Managed Care, Partnership, Patient, Foot, Sale, Acquisition, Ankle, MD, ASC, Extremities, Internationalized domain name, Wrist, Outpatient surgery

Henry Schein announced the agreement to acquire a majority interest of TriMed on December 20, 2023.

Key Points: 
  • Henry Schein announced the agreement to acquire a majority interest of TriMed on December 20, 2023.
  • The addition of TriMed will strengthen Henry Schein’s deep and longstanding relationship with existing Integrated Delivery Networks (IDNs) and Ambulatory Surgery Center (ASC) customers by providing a wider range of surgical solutions.
  • This reflects the Company’s strategy to expand the sale of Henry Schein-owned brands to new and existing customers.
  • Henry Schein expects the transaction to be neutral to 2024 non-GAAP earnings per share and accretive thereafter.

Paragon 28 Adds to Suite of Novel Syndesmosis Repair Solutions with Launch of Grappler® R3INFORCE™ Extraosseous Repair System

Retrieved on: 
Thursday, March 28, 2024
General Health, Health, Surgery, Medical Devices, Paragon, Surgeon, Mechanics, Foot, Ankle, Ligament, FNA, Creativity, Injury, Multimedia, Video game

View the full release here: https://www.businesswire.com/news/home/20240328312304/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20240328312304/en/
    Figure 1: Anterior inferior tibiofibular ligament (“AITFL”) Repair Showing the Grappler® R3INFORCE™ Dynamic Anchor (left) and Grappler® Knotless Anchor (center).
  • The Grappler® R3INFORCE™ Extraosseous Repair System is sterile packed and includes all instrumentation needed to complete the case in multiple configurations, reducing waste and intraoperative complexity.
  • It offers surgeons a comprehensive, physiological, and anatomical reconstruction system for ankle syndesmotic injuries.”
    The Grappler® R3INFORCE™ Extraosseous Repair System bolsters Paragon 28’s soft tissue offering, which includes the Paratrooper™ Plantar Plate System, TenoTac™ 2.0 Soft Tissue Fixation System, Grappler® Interference Screw System, Grappler® Suture Anchor System, Grappler® Knotless Anchor System, Bridgeline™ Tape, R3ACT® Stabilization System, R3LEASE™ Stabilization System, and Mister Tendon™ Harvester.
  • With this comprehensive portfolio, Paragon 28® provides its customers with a single source to address their foot and ankle soft tissue needs.

Nabla Expands Clinical Leadership Team, Appoints Dr. Andrew Lundquist as Clinical Director

Retrieved on: 
Thursday, April 4, 2024
Ankle, AI, Quality, Marketing, Foot, Strategic planning, Human, Medicine, Medical device

Dr. Lundquist brings 16 years of experience as a board-certified foot and ankle surgeon.

Key Points: 
  • Dr. Lundquist brings 16 years of experience as a board-certified foot and ankle surgeon.
  • Dr. Lundquits's expertise within the mid-sized clinical market will complement Nabla's Chief Medical Officer Dr. Lee' s expertise with large health systems.
  • After having evaluated existing solutions, Dr. Lundquist helped roll out Nabla Copilotto its network of nearly 200 clinicians following a successful pilot and advising Nabla throughout the process.
  • "Having him join Nabla as our Clinical Director is a big step forward in our vision to restore joy to the practice of medicine.

Arthrex Commemorates 10th Anniversary of InternalBrace™ Technique

Retrieved on: 
Tuesday, April 2, 2024
Tears, UHMWPE, Patient, Ankle, Surgeon, Ligament, Love, Injury, Dentistry

NAPLES, Fla., April 2, 2024 /PRNewswire/ -- Arthrex, a global leader in minimally invasive surgical technology, announced the 10th anniversary of the InternalBrace™ ligament augmentation system.

Key Points: 
  • NAPLES, Fla., April 2, 2024 /PRNewswire/ -- Arthrex, a global leader in minimally invasive surgical technology, announced the 10th anniversary of the InternalBrace™ ligament augmentation system.
  • "This pioneering surgical technique, developed in collaboration with leading surgeons around the world and supported by more than 213 peer-reviewed studies, has become the gold standard in the treatment of soft-tissue and musculoskeletal injuries," said Arthrex President and Founder Reinhold Schmieding.
  • The technique was initially developed to support lateral ankle instability repair during the post-surgery healing phase.
  • "3
    The procedure augments the primary surgical repair using special anchors to provide additional points of fixation that hold the ligament to a patient's ankle bone while they heal.